top of page

NCI-2022-07395

A Phase 1 Study Investigating AGEN1571 as a Single Agent and in Combination with a PD-1 Inhibitor and/or Botensilimab (AGEN1181) in Patients with Advanced Solid Tumors


This is an early-stage, open-label medical study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of LY3176150, an investigational drug, in combination with pembrolizumab. LY3176150 is a type of drug called a RET inhibitor. RET inhibitors target a protein called RET, which can play a role in the growth and survival of cancer cells. Pembrolizumab is a type of immunotherapy drug called a PD-1 inhibitor. It helps the immune system attack cancer cells by blocking a protein called PD-1 that can sometimes hide cancer cells from the immune system. The study is open to adults with advanced solid tumors who have not received prior treatment with a RET inhibitor or anti-PD-1 therapy.


Early-stage: Early phase (phases I and II) studies help researchers determine: Whether a new treatment is safe, what its side effects are and the best dose of the new treatment.

Open-label: Patients know which treatments are being given to them


For more information about the trial, click the link below:

NCI-2022-07395

Clinical Trial Site: Sinai


To see all available clinical trials click here.



Recent Posts

See All

NCI-2022-06272

A first-in-human, phase 1/2, open-label, multi-center, dose-escalation and dose-expansion study to evaluate safety, tolerability, pharmacokinetics, and anti-tumor activity of the ATR inhibitor IMP9064

NCI-2019-04202

A Multi-Cohort Exploratory Study of Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC. Some patients have a tumor that is “resectable,” which means that it is able to be rem

NCI-2022-05056

Tislelizumab Consolidation after Liver-Directed Therapy for Hepatocellular Carcinoma (Phase II Study) This is a medical study to evaluate the safety and efficacy of tislelizumab in combination with ot

Comentarios


bottom of page